Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EBT (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed EBT for 7 consecutive years, with -$78.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 33.62% to -$78.2 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$263.7 million, a 36.42% decrease, with the full-year FY2025 number at -$263.7 million, down 36.42% from a year prior.
  • EBT was -$78.2 million for Q4 2025 at Nurix Therapeutics, up from -$86.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$24.2 million in Q1 2021 to a low of -$86.4 million in Q3 2025.
  • A 5-year average of -$44.9 million and a median of -$42.6 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 101.76% in 2021, then surged 46.53% in 2023.
  • Nurix Therapeutics' EBT stood at -$37.7 million in 2021, then dropped by 24.06% to -$46.7 million in 2022, then increased by 10.19% to -$42.0 million in 2023, then tumbled by 39.53% to -$58.5 million in 2024, then plummeted by 33.62% to -$78.2 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's EBT are -$78.2 million (Q4 2025), -$86.4 million (Q3 2025), and -$42.7 million (Q2 2025).